HDL subfractions analysis: A new laboratory diagnostic assay for patients with cardiovascular diseases and dyslipoproteinemia

Neuroendocrinology Letters

Volumn 32, Issue 4, 2011, Pages 502-509

  Oravec, Stanislav ^a   Dostal, Elisabeth ^b   Dukát, Andrej ^a   Gavorník, Peter ^a   Kučera, Marek ^a   Gruber, Kristina ^c  

^a Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

^b Krankenanstalten Dr Dostal   (Austria)

^c GENERAL HOSPITAL KLAGENFURT   (Austria)

Author keywords

Arterial hypertension; Atherogenic lipoprotein phenotype; Coronary heart disease; HDL 1 10 subfractions; Non aherogenic hyper betalipoproteinemia LDL1,2

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DYSLIPOPROTEINEMIA; FEMALE; HUMAN; HYPERLIPOPROTEINEMIA TYPE 2; HYPERTENSION; ISCHEMIC HEART DISEASE; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POLYACRYLAMIDE GEL ELECTROPHORESIS; QUANTITATIVE ANALYSIS;

EID: 80053495604     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Alabakovska SB, Todorova BB, Labudovic DD, Tosheska KN (2002) Gradient gel electrophoretic separation of LDL and HDL subclasses on BioRad Mini Protean II and size phenotyping in healthy Macedonians. Clin Chim Acta. 317(1-2): 119-123. (Pubitemid 34114026)
2. Asztalos BF, Cupples LA, Demissie S, Horvath KV, Cox CE, Batista MC, Schaefer EJ (2004) High density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol. 24(11): 2181-2189.
3. Austin MA, King MC, Vranizan KM, Krauss RM (1990). Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation. 82(2): 495-506. (Pubitemid 20257828)
4. Berneis KK, Krauss RM (2002) Metabolic origins and clinical significance of LDL Heterogeneity. J Lipid Res. 43(9): 1363-1379.
5. Castelli WP (1988) Cholesterol and lipids in the risk of coronary artery disease - The Framingham Heart Study. Can J Cardiol. 4(Suppl A): 5A-10A.
6. Castelli WP (1992) Epidemiology of triglycerides; a view from Framingham. Am J Cardiol. 70(19): H3-H9.
7. Castelli WP (1998) The new pathophysiology of coronary artery disease. Am J Cardiol. 82(Suppl2): 60-85.
8. Chait A., Brazo RL, Tribble DL, Krauss RM (1993) Susceptibility of small, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Amer J Med. 94(4): 350-356. (Pubitemid 23106620)
9. Despres JP (2007) Cardiovascular disease under the influence of excess visceral fat. Crit Pathw Cardiol. 6(2): 51-59.
10. Hoefner DM, Hodel SD, O'Brien JF, Branum EL, Sun D, Meissner I, McConnell JP (2001) Development of a rapid quantitative method for LDL subfraction with use of the Quantimetrix Lipoprint LDL system. Clin Chem. 47(2): 266-274. (Pubitemid 32142925)
11. Kostner GM, Laggner P (1989) Chemical and physical properties of lipoproteins. In: Fruchart JC, Shepherd J (eds). Clinical Biochemistry - Human Plasma Lipoproteins. Berlin, New York, Walter de Gruyter, 23-54.
12. Kostner GM, Scharnagl H, Kostner K, März W (2007) Zusammensetzung und Stoffwechsel der Lipoproteine. In: Schwandt P, Parhofer KG (eds) Handbuch der Fettstoffwechselstörungen. Dyslipoproteinämien und Atherosklerose: Diagnostik, Therapie und Prävention, 3.Auflage, Stuttgart, New York, Schattauer, 2-65.
13. th Annual meeting, Philadelphia, PA, July 2003.
14. Morais J (2005) Quantimetrix shows that all HDL subfractions may not protect against heart disease. AACC international congress of Clinical Chemistry, Orlando FL, june 2005.
15. th Annula meting, Orlando FL, July 2005.
16. Muniz N, Morais J (2005) Coronary heart disease. High density lipoprotein subclasses associated with heart disease. Medical Letter on the CDL and FDA July 31st 2005.
17. Oravec S (2006) Nová laboratórno-medicínska pomoc c diagnostike dyslipoproteínemií a kardiovaskulárnych ochorení: Identifikácia LDL podskupin (A new laboratory-medical support in the diagnostics of dyslipoproteinemia and cardiovascular diseases) Med Milit Slov. 8(1): 28-32.
18. Oravec S, Gruber K, Dostal E, Mikl J (2011) Hyper-betalipoproteinemia LDL 1,2: A newly identified nonatherogenic hypercholesterolemia in a group of hypercholesterolemic subjects. Neuroendocrinol Lett. 32(3): 322-327.
19. Otvos JD, Jeyarajah EJ, Bennet SW, Krauss RM (1992). Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma protein concentrations and subspecies distribution from a single, rapid measurement. Clin Chem. 38(9):1632-1638.
20. Packard CJ (2003) Triacylglycerol-rich lipoproteins and the generation of small dense low-density lipoprotein. Biochem Soc Trans. 31(5): 1066-1069.
21. Rainwater DL, Moore PH jr, Shelledy WR, Dyer TD, Slifer SH (1997) Characterization of a composite gradient gel for the electrophoretic separation of lipoproteins. J Lipid Res. 38(6): 1261-1266. (Pubitemid 27281820)
22. van J, Pan J, Charles MA, Krauss R, Wong N, Wu X (2007) Atherogenic lipid phenotype in a general group of subjects. Arch Pathol Lab Med. 131(11): 1679-1685. (Pubitemid 350077465)